Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 51655-698

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 51655-698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 698 52 Master Bottle Label Approval Rev A 03 21)

Label for Valsartan and Hydrochlorothiazide tablets, USP 160 mg/12.5 mg, film-coated, oral dosage form. The package contains 30 tablets and is labeled Rx only. Manufacturer is Northwind Health Company, LLC. Storage instructions include keeping at 20°C (68-77°F) with excursions permitted between 15-30°C (59-86°F), storing in original container, and protecting from moisture.*

FDA Label Image

Figure-1 (Valsartan Hctz Figure 1)

A line graph showing the percentage of subjects achieving systolic blood pressure (SBP) under 140 mmHg versus baseline SBP (mmHg). Four treatment groups are compared: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by distinct symbols and lines indicating efficacy trends across baseline SBP values.*

FDA Label Image

Figure-2 (Valsartan Hctz Figure 2)

A line graph showing the percentage of patients with diastolic blood pressure (DBP) under 90 mmHg versus baseline DBP values in mmHg. The graph compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with distinct markers for each group. It illustrates relative DBP control efficacy among these treatments.*

FDA Label Image

Figure-3 (Valsartan Hctz Figure 3)

A line graph showing the percentage of patients achieving systolic blood pressure under 130 mmHg (% SBP<130) plotted against baseline systolic blood pressure (SBP) in mmHg. The graph compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, illustrating treatment effects on SBP reduction.*

FDA Label Image

Figure-4 (Valsartan Hctz Figure 4)

A line graph depicting the percentage of diastolic blood pressure (DBP) below 80 mmHg versus baseline DBP (mmHg). The graph compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, showing distinct data trends for each treatment group across baseline DBP values from 90 to 110 mmHg.*

FDA Label Image

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)

Chemical structure diagram of the active ingredient Valsartan and Hydrochlorothiazide, showing molecular bonds and functional groups characteristic of these compounds.*

FDA Label Image

Valsartan-str (Valsartan Hctz Valsartan)

Chemical structure of valsartan, one of the active ingredients in the Valsartan and Hydrochlorothiazide tablet combined drug product by Northwind Health Company, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.